Capital Research Global Investors
ADMA icon

Capital Research Global Investors’s ADMA Biologics ADMA Stock Holding History

Capital Research Global Investors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$73.3M Sell
8,756,374
-2,434,742
-22% -$22.2M 0.01% 323
2026
Q1 		$101M Buy
11,191,116
+4,553,644
+69% +$71.9M 0.02% 312
2025
Q4 		$121M Buy
6,637,472
+3,383,559
+104% +$57M 0.02% 283
2025
Q3 		$47.7M Buy
+3,253,913
New +$55.8M 0.01% 352

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Capital Research Global Investors's ADMA Position: Q2 2026 in Review

Capital Research Global Investors reduced its ADMA Biologics (ADMA) stake by 22% in Q2 2026, selling an estimated $22.2M and leaving 8,756,374 shares worth $73.3M. The position accounts for 0.01% of the portfolio, ranked #323.

Capital Research Global Investors first reported a position in ADMA in Q3 2025 and has held it in 4 quarters since. The position peaked at $121M in Q4 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Capital Research Global Investors held 8,756,374 shares of ADMA Biologics worth $73.3M as of Q2 2026.
  • Capital Research Global Investors sold 2,434,742 ADMA Biologics shares in Q2 2026, an estimated $22.2M.
  • ADMA Biologics made up 0.01% of Capital Research Global Investors's portfolio in Q2 2026, its #323 holding.
  • Capital Research Global Investors first reported a position in ADMA Biologics in Q3 2025 and has held it in 4 quarters since.
  • Capital Research Global Investors's ADMA Biologics position peaked at $121M in Q4 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Capital Research Global Investors's 13F filing for Q2 2026, filed 12 Aug 2026.